Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 54,298 Shares of Stock

by · The Cerbat Gem

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) CEO Christopher Richard Anzalone sold 54,298 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $62.58, for a total transaction of $3,397,968.84. Following the transaction, the chief executive officer owned 3,916,957 shares in the company, valued at approximately $245,123,169.06. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Christopher Richard Anzalone also recently made the following trade(s):

  • On Monday, December 15th, Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $68.85, for a total transaction of $8,950,500.00.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $64.66 on Wednesday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $72.36. The stock’s 50 day moving average is $46.66 and its two-hundred day moving average is $30.26. The firm has a market capitalization of $8.79 billion, a PE ratio of -808.15 and a beta of 1.28. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. iSAM Funds UK Ltd purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $29,000. Salomon & Ludwin LLC purchased a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Federated Hermes Inc. acquired a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $52,000. Smartleaf Asset Management LLC increased its position in Arrowhead Pharmaceuticals by 2,186.5% during the third quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,618 shares in the last quarter. Finally, Virtus Advisers LLC purchased a new position in Arrowhead Pharmaceuticals during the second quarter worth $34,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the topic of a number of recent analyst reports. Piper Sandler upped their price objective on Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Bank of America increased their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. HC Wainwright raised their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. The Goldman Sachs Group upped their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a research report on Thursday, November 20th. Finally, Royal Bank Of Canada increased their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $58.56.

Read Our Latest Report on ARWR

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Recommended Stories